Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:51:41.347Z.
Calculation as of: 2026-10-06T17:51:41.347Z.
Quote observation: 2026-10-06T17:42:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 325841a12d79c3b22e4488d0564adef7d4bfa7ba78e5cc1d4c3dcb4b1cd6f762
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$1.42M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.50M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genprex, Inc. (GNPX) | $1.34M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.42M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.32M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A | N/A | N/A | N/A |
| NEXGEL, Inc. (NXGL)vs › | $1.44M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | N/A | 7.82 | 7.82 | 7.82 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.50M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.50M | N/A | 56.34 | 56.34 | 56.34 |
| PMGC Holdings Inc. (ELAB)vs › | $1.47M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.18M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
